1. Home
  2. GCV vs ACRV Comparison

GCV vs ACRV Comparison

Compare GCV & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Convertible and Income Securities Fund Inc. (The)

GCV

Gabelli Convertible and Income Securities Fund Inc. (The)

HOLD

Current Price

$4.37

Market Cap

85.1M

Sector

Finance

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.02

Market Cap

95.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCV
ACRV
Founded
1988
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.1M
95.0M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
GCV
ACRV
Price
$4.37
$2.02
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$13.00
AVG Volume (30 Days)
57.9K
3.3M
Earning Date
01-01-0001
11-13-2025
Dividend Yield
13.04%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$805.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.15
$1.05
52 Week High
$4.58
$8.00

Technical Indicators

Market Signals
Indicator
GCV
ACRV
Relative Strength Index (RSI) 61.43 45.66
Support Level $4.31 $1.57
Resistance Level $4.34 $3.56
Average True Range (ATR) 0.07 0.31
MACD 0.01 -0.06
Stochastic Oscillator 94.41 22.36

Price Performance

Historical Comparison
GCV
ACRV

About GCV Gabelli Convertible and Income Securities Fund Inc. (The)

GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive and others. All the operation of the group is operated through the regions of United States.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Share on Social Networks: